Lilly suspends contributions to 4 Indiana Congress members over certification votes
Several other Indiana companies also say they are suspending contributions to all candidates or are taking a close look at the matter.
Eli Lilly and Co.
Articles
In midst of pandemic, drugmakers raise prices on hundreds of prescription drugs
So far this month, drugmakers have hiked prices on 636 drugs, according to research by GoodRx, which tracks prescription drug prices and offer a mobile app to help consumers find the lowest prices on hundreds of drugs.
Lilly shares surge after its potential Alzheimer’s drug slows cognitive decline
The experimental drug, donanemab, could be a huge breakthrough for Lilly, which has spent billions of dollars over 30 years researching treatments for Alzheimer’s disease, only to see them fall short in clinical trials.
Lilly’s COVID treatment sparks little demand
For a highly touted drug meant to keep throngs of people out of hospitals during a pandemic, Eli Lilly and Co.’s wonder treatment bamlanivimab sure has been slow to catch on.
Demand surprisingly low for COVID-19 antibody drugs, but shortages still loom
Red tape, staff shortages, testing delays and strong skepticism are keeping many patients and doctors from the drugs made by Eli Lilly and Co. and Regeneron Pharmaceuticals.
Eli Lilly shares rise on Prevail acquisition, optimistic forecast
Lilly stock climbed Tuesday after the drugmaker laid out a better-than-expected revenue forecast and plans to buy a young company developing a potential Parkinson’s disease treatment.
Lilly acquiring gene therapy startup for up to $1 billion
Eli Lilly and Co. on Tuesday announced that it is buying New York-based Prevail Therapeutics Inc., an emerging player in the sizzling-hot area of gene therapies, which targets Parkinson’s disease and other brain-related maladies.
Study: Drug combo with Lilly medication boosts COVID recovery time
Doctors are reporting that a two-drug treatment involving a medication from Indianapolis-based Eli Lilly and Co. is especially helpful for COVID-19 patients who need extra oxygen.
CVS to give Eli Lilly therapy to COVID-19 patients at home
The medication will be provided by the U.S. government, which paid Indianapolis-based Lilly $375 million for an initial two-month supply of 300,000 doses as part of the Operation Warp Speed program.
Lilly starting new trial for COVID-19 antibody, potentially widening already red-hot market
Lilly said it will enroll up to 500,000 people in its latest study, with at least 5,000 people expected to receive bamlanivimab therapy. The drugmaker is partnering with health insurer UnitedHealth Group to see if the drug will help high-risk people.
Business leaders say focus must remain on racial inequality for years to come
During IBJ’s Engage Indiana 2020 virtual event Thursday morning, Eli Lilly & Co. CEO Dave Ricks said he always believed enhancing diversity and inclusion was important, but this year showed him how serious a problem racial injustice is and fueled his motivation to do more to address it.
CVS prepares to administer Lilly antibody drug, as feds buy 650,000 more doses for $812.5M
CVS has developed a program to provide the treatments in their homes, but it won’t be available—at least initially—in Indianapolis.
Health experts clash over use of certain drugs for COVID-19
In a separate development, the FDA on Thursday gave emergency authorization to use of another anti-inflammatory drug sold by Eli Lilly, baricitinib, to be used with remdesivir.
Lilly arthritis drug gets FDA emergency use authorization for COVID-19 patients
The Indianapolis drugmaker said Thursday evening it was awarded an emergency use authorization for its drug baricitinib to be used in combination with Gilead Sciences’ antiviral drug remdesivir in severely ill, hospitalized patients with COVID-19.
Trump officials promise fair distribution of Lilly’s new COVID-19 antibody drug
Because of the initial limited supply, the number of doses each state receives will be determined by the number of confirmed cases and hospitalizations in a given week, federal officials said.
Lilly’s COVID-19 treatment expected to be in short supply initially
The initial scarcity of the drug and the logistical complexities of administering it could mute its immediate impact on the pandemic and raise questions about whether it is being distributed to people in the greatest need.
U.S. allows emergency use of Lilly’s COVID-19 antibody drug
The Food and Drug Administration on Monday cleared the experimental drug from Indianapolis-based Eli Lilly and Co. for people 12 and older with mild or moderate COVID-19 not requiring hospitalization. It’s a one-time treatment given through an IV.
Lilly signs $375M deal with government for experimental COVID-19 treatment
Eli Lilly and Co. said Wednesday that the U.S. government will accept 300,000 vials of the drug, called bamlanivimab, if the Food and Drug Administration grants emergency authorization for its use.
Lilly still bullish on COVID-19 therapy, despite end of trial
Although federal officials pulled the plug on a trial testing a Lilly antibody drug for people hospitalized with COVID-19, other studies for the therapy are continuing on populations that could become big markets.
UPDATED: Lilly antibody drug fails in COVID-19 study for hospitalized patients
The discontinuation of the study, along with the release of third-quarter earnings that fell short of analysts’ expectations, caused Lilly shares to fall 3.5% in premarket trading Tuesday.